93%

Reduction in Pain1

Cartiva patients have experienced nearly the same substantial reduction in pain as fusion patients.

Cartiva pain reduction data

168%

Functional Improvement2

Cartiva patients demonstrate long-lasting, substantial improvement in foot function.

Cartiva functional improvement data

50%

Improved Range of Motion3

Cartiva doesn't just preserve range of motion, but substantially increases it.

Cartiva range of movement data
The only product of its kind backed By Level I Clinical Evidence

The result of the largest clinical study of the MTP joint to date. The only FDA-approved alternative to fusion.

An Advanced Solution

Patient Satisfation

Pain relief, increased motion, and quicker recovery time mean happier patients.

40% Faster than Fusion

The entire Cartiva® surgery only takes about 35 minutes to complete.

Burns no Bridges

The use of Cartiva does not prevent the implementation of fusion in the future.

Proven Durability

Significant pain reduction and functional improvement at five years (N=27).*

 

Watch Implant Placement 5 Year Clinical Data

 

* Daniels TR, Younger SE, Penner MJ, et al. Foot Ankle Int. 2017;38(3):243-247. Limited to five year data from a subset of study participants (N=27). Additional data from other sites and subjects not yet available.

Cartiva is an effective option for patients wishing to maintain their range of motion while getting significant pain relief.

Selene G. Parekh, MD, MBA, Prof of Orthopedic Surgery, Duke University

CONTACT US

Interested in offering Cartiva® to patients?

Fill out the form below for more details.

I'd like more information about Cartiva®
I'd like to schedule a demonstration

Footnotes

1 A substantial and clinically meaningful reduction in pain using the Visual Analog Scale (VAS) was experienced by subjects in the Cartiva group at every follow-up visit through 2 years. Cartiva subjects demonstrated a 93% reduction from a score of 68 at baseline to 5 at 2 years.

2 Functional activities were evaluated using the validated Foot and Ankle Mobility Measure (FAAM). Substantial improvement was observed for Cartiva subjects throughout the 2-year follow-up period with a 168% improvement observed in the sporting activities scale.

3 There was a substantial and clinically important improvement in active dorsiflexon motion in the Cartiva group, restoring motion to levels which are documented in the literature to be needed for normal walking gait while experiencing substantial reduction in pain.

© 2008-2018. All Rights Reserved
Company Reg. No: 6545496